Determination of c-erbB-2/Her-2/Neu status in breast cancer: Comparative analysis between immunoenzymatic assay (ELISA) and immunohistochemistry;Determinación de c-erbB-2/Her-2/Neu en el cáncer de mama: análisis comparativo entre análisis inmunoenzimático (ELISA) e inmunohistoquímico

Clinical and Translational Oncology

Volumn 5, Issue 5, 2003, Pages 272-279

  Lamelas Suárez Pola, María L ^a   González Vázquez, Luis O ^a   Díaz, Antonio Rodil ^a   García, Miguel Bongera ^a   Rojo, Julio Vázquez ^a   Allende, María T ^a   Piñeiro, Francisco Vizoso ^a  

^a HOSPITAL DE JOVE   (Spain)

Author keywords

Breast cancer; C erbB 2; ELISA assay; Immunohistochemistry; P185HER

Indexed keywords

EID: 27644450096     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4:362-6.
2. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding an 185,000-Mr tumor antigen. Nature 1984;312:513-6.
3. King CR, Kraus MH, Aaronson SA. Amplification of a novel c-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-6.
4. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-30.
5. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112 Suppl 1:s53-67.
6. Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpresion in breast carcinoma. J Cell Physiol 2000;182:150-62.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987;235:177-82.
8. Borg A, Baldertorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroidreceptor positive breast cancer. Cancer Lett 1994;81: 137-44.
9. Carlomagno C, Perrone F, Gallo C, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.
10. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB-2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220-6.
11. Yu D, Hung M-Ch. Role of erbB2 in breast cancer chemosensitivity. BioEssays 2000;22:673-80.
12. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
13. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol 1999;12:827-34.
14. Hanna W. Testing for HER2 status. Oncology 2001; 61:22-30.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
16. McKenzie SJ, Marks PJ, Lam T, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989;4:543-8.
17. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997;10:720-7.
18. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64.
19. Van de Vijver MJ. Assessment of the need and appropiate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001;37:11-7.
20. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB2 oncoprotein in human breast carcinomas: Immunohistological assessment lates with gene amplification. Lancet 1987;ii:69-72.
21. Van de Vijver MJ, Mooi WJ, Peterse JL, Nusse R. Amplification and over-expression of the neu oncogene in human breast carcinomas. Eur J Surg Oncol 1988;14:111-4.
22. Walker RA, Gullick WJ, Varley JM. An evaluation immunoreactivity for c-erbB2 protein as a marker short-term prognosis in breast cancer. Br J Cancer 1989;60:426-9.
23. Kakar S, Puangsuvan N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and correlation with survival. Mol Diagnosis 2000;5:199-207.
24. Valeron PF, Chirino R, Vega V, et al. Quantitative analysis of p185 (HER-2/neu) protein in breast cancer and its association with other prognostic factors. Int J Cancer 1997;74:175-9.
25. Koscielny S, Terrier P, Daver A, et al. Quantitative determination of c-erbB-2 in human breast tumors: potential prognostic significance of low values. Eur J Cancer 1998;34:476-81.
26. Bermont L, Algros MP, Baron MH, Adessi GL. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma. Breast Cancer Res 2000; 63:163-9.
27. Dittadi R, Brazzale A, Pappagallo G, et al. ErbB2 assay in breast cancer: Possibly improved clinical information using a quantitative method. Anticancer Res 1997;17: 1245-8.
28. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198: 165-84.
29. Eppenberger-Castori S, Kueng W, Benz C, et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645-56.
30. Dittadi R, Catozzi L,Gion M, et al. Comparison between Western blotting, immunohistochemical and ELISA assay for 185neu quantitation in breast cancer specimens. Anticancer Res 1993;13:1821-4.
31. Cuny M, Simony-Lafontaine J, Rouanet P, et al. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations. Oncol Res 1994;6:169-76.
32. Pifanelli A, Dittadi R, Catozzi L, et al. Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res 1996;37:267-76.
33. Sugano K, Ushiama M, Fukutomi T, Tsuda H, Krroh T, Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000;89:329-36.
34. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
35. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birubaum D, Jacquemier J. Optimization of immunohistochemical detection of erbB2 in human breast cancer: impact of fixation. J Pathos 1994;173:65-75.
36. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in the immunohistochemical studies of oncogene expression. Cancer Res 1994; 54:2771-7.
37. Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M. CerbB2 immunostaining: Problems with interpretation. J Clin Pathol 1994;47:816-22.
38. Wisecarver JL. Her-2/neu testing comes of age. Am J Clin Pathos 1999;111:299-301.